Pacira Pharma (PCRX) Tops Q3 EPS by 7c

Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.72, $0.07 better than the analyst estimate of $0.65. Revenue for the quarter came in at $127.7 million versus the consensus estimate of $130.38 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Honeywell (HON) Tops Q1 EPS by 8c, Beats on Revenue; Offers FY Guidance
• Oshkosh Corp. (OSK) Tops Q1 EPS by 64c
• Willis Towers Watson (WTW) Tops Q1 EPS by 4c, provides guidance